Anzeige
Meldung des Tages: Billigdrohnen verändern Kriege – startet hier der nächste Milliarden-Profiteur?

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
211,89 $
-7,87 $
-3,58%
184,09 € 17:38:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,02%
Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,00: VH3ME8
Werbung

AbbVie News

13.03.26 - dpa-AFX
ROUNDUP: Botox und Co. - Minimalinvasive Eingriffe immer gefragter
Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören zum Beispiel Behandlungen mit Botox ...
09.03.26 - PR Newswire
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-​Acting Amylin Analog, in Adults PR Newswire
04.03.26 - PR Newswire
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS PR Newswire
03.03.26 - PR Newswire
AbbVie to Present at the Leerink Partners Global Healthcare Conference
AbbVie to Present at the Leerink Partners Global Healthcare Conference PR Newswire
02.03.26 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease PR Newswire
24.02.26 - PR Newswire
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference PR Newswire
23.02.26 - PR Newswire
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States PR Newswire
21.02.26 - wallstreetONLINE Redaktion
Community Rückblick: wO-User zur Newron Kapital­erhöhung: "Tja, wir wurden wohl mächtig verarscht"
Newron ist zurück an der Spitze der wallstreetONLINE-​Diskussionen. Grund: Bis zu 38 Mio. € Finanzierung für das Phase-​III-Programm Evenamide (Schizophrenie). Die Community ...
20.02.26 - wallstreetONLINE Redaktion
Pharma-Dividenden-Wert: AbbVie greift auf dem Abnehm-Markt an: Wird das die nächste Milliarden-Chance?
GLP-1-Abnehmpräparate bringen neue Kunden in Beauty-​Praxen – und setzen AbbVies Faltenmittel Juvéderm unter Druck. Die Analysten von Berenberg sehen zugleich neue ...
20.02.26 - PR Newswire
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic ...
19.02.26 - PR Newswire
AbbVie Declares Quarterly Dividend
AbbVie Declares Quarterly Dividend PR Newswire
17.02.26 - ARIVA.DE Redaktion
AbbVie: Immunologie-Marktführer mit wachsendem Onkologie-Potenzial – Chance trotz Humira-Druck?
AbbVie festigt seine dominierende Stellung in der Immunologie und baut parallel ein wachstumsstarkes Onkologie-​Portfolio auf. Trotz des anhaltenden Gegenwinds durch den ...
10.02.26 - PR Newswire
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market PR Newswire
04.02.26 - PR Newswire
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
AbbVie Reports Full-Year and Fourth-​Quarter 2025 Financial Results PR Newswire
03.02.26 - PR Newswire
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program PR Newswire
03.02.26 - PR Newswire
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo PR Newswire
30.01.26 - PR Newswire
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
$170B Patent Cliff Ignites Biotech Deal Wave: Late-​Stage Platforms Command Premium PR Newswire
29.01.26 - PR Newswire
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships PR Newswire
28.01.26 - PR Newswire
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine ...
16.01.26 - PR Newswire
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell ...

Newssuche

Videos

newspaper
16.03.26 -3,24%
Technical Trading: 82 Prozent Trefferquote
S&P 500 Long Typ: Open End Turbo WKN: VG93RW Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »